News & Views
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical…
Read more
Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)…
Read more
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January…
Read more
Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical…
Read more
News,
Telix is pleased to provide details of BioSpectrum Asia interview with Telix Japan President & COO Dr Shintaro Nishimura on the APAC oncology market & opportunities/challenges in the Japanese market…
Read more
News,
Telix Pharmaceuticals Limited is delighted to announce the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European…
Read more
News,
Telix Pharmaceuticals Limited is pleased to announce the establishment Telix Pharmaceuticals (Japan) Ltd and appointment of the first two members of the Japanese leadership…
Read more
Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center…
Read more
News,
Telix has today announced the appointment of Dr. Bernard Lambert as President and Chief Operating Officer (COO) of Telix’s US…
Read more
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised…
Read more